Impact of ROS-Dependent Lipid Metabolism on Psoriasis Pathophysiology
Psoriasis is the most common autoimmune disease, yet its pathophysiology is not fully understood. It is now believed that psoriasis is caused by the increased activation of immune cells, especially Th1 lymphocytes. However, in psoriasis, immune cells interfere with the metabolism of keratinocytes, leading to their increased activation. Therefore, the pathophysiology of psoriasis is currently associated with the overproduction of ROS, which are involved in the activation of immune cells and keratinocytes as well as the modulation of various signaling pathways within them. Nevertheless, ROS modulate the immune system by also boosting the increasing generation of various lipid mediators, such as products of lipid peroxidation as well as endocannabinoids and prostaglandins. In psoriasis, the excessive generation of ROS and lipid mediators is observed in different immune cells, such as granulocytes, dendritic cells, and lymphocytes. All of the above may be activated by ROS and lipid mediators, which leads to inflammation. Nevertheless, ROS and lipid mediators regulate lymphocyte differentiation in favor of Th1 and may also interact directly with keratinocytes, which is also observed in psoriasis. Thus, the analysis of the influence of oxidative stress and its consequences for metabolic changes, including lipidomic ones, in psoriasis may be of diagnostic and therapeutic importance.
Top-30
Journals
|
1
2
3
|
|
|
Redox Biology
3 publications, 8.82%
|
|
|
International Journal of Molecular Sciences
3 publications, 8.82%
|
|
|
Experimental Dermatology
2 publications, 5.88%
|
|
|
Antioxidants
2 publications, 5.88%
|
|
|
Life
1 publication, 2.94%
|
|
|
Molecular Pharmaceutics
1 publication, 2.94%
|
|
|
Journal of Investigative Dermatology
1 publication, 2.94%
|
|
|
Theriogenology
1 publication, 2.94%
|
|
|
Journal of Immunology
1 publication, 2.94%
|
|
|
Archives of Dermatological Research
1 publication, 2.94%
|
|
|
Nanomaterials
1 publication, 2.94%
|
|
|
Journal of Clinical Medicine
1 publication, 2.94%
|
|
|
European Journal of Pharmaceutical Sciences
1 publication, 2.94%
|
|
|
Reproduction in Domestic Animals
1 publication, 2.94%
|
|
|
International Journal of Pharmaceutics
1 publication, 2.94%
|
|
|
Materials Today Bio
1 publication, 2.94%
|
|
|
Therapeutic Apheresis and Dialysis
1 publication, 2.94%
|
|
|
Frontiers in Bioscience-Landmark
1 publication, 2.94%
|
|
|
Molecular Omics
1 publication, 2.94%
|
|
|
Medicina
1 publication, 2.94%
|
|
|
European Journal of Medical Research
1 publication, 2.94%
|
|
|
Genes and Diseases
1 publication, 2.94%
|
|
|
International Journal of Nanomedicine
1 publication, 2.94%
|
|
|
Molecular Biomedicine
1 publication, 2.94%
|
|
|
Frontiers in Immunology
1 publication, 2.94%
|
|
|
Colloids and Surfaces A: Physicochemical and Engineering Aspects
1 publication, 2.94%
|
|
|
Naunyn-Schmiedeberg's Archives of Pharmacology
1 publication, 2.94%
|
|
|
1
2
3
|
Publishers
|
2
4
6
8
10
|
|
|
Elsevier
10 publications, 29.41%
|
|
|
MDPI
9 publications, 26.47%
|
|
|
Springer Nature
5 publications, 14.71%
|
|
|
Wiley
4 publications, 11.76%
|
|
|
American Chemical Society (ACS)
1 publication, 2.94%
|
|
|
The American Association of Immunologists
1 publication, 2.94%
|
|
|
IMR Press
1 publication, 2.94%
|
|
|
Royal Society of Chemistry (RSC)
1 publication, 2.94%
|
|
|
Taylor & Francis
1 publication, 2.94%
|
|
|
Frontiers Media S.A.
1 publication, 2.94%
|
|
|
2
4
6
8
10
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.